Edgar Filing: Aeglea BioTherapeutics, Inc. - Form 4

•	Therapeutics, Inc.									
Form 4	16									
May 19, 20	ЛЛ								PPROVAL	
	UNITED	STATES		RITIES A shington,			COMMISSION	OMB Number:	3235-0287	
Check th if no lon subject to Section Form 4 Form 5 obligation may cor <i>See</i> Insta 1(b).	rsuant to S (a) of the I	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940					January 31 2005 Estimated average burden hours per response 0.5			
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> GEORGIOU GEORGE			2. Issuer Name and Ticker or Trading Symbol Aeglea BioTherapeutics, Inc. [AGLE]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
	. ,			of Earliest Tr Day/Year) 2016	ransaction		X Director Officer (give below)		% Owner her (specify	
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
AUSTIN, 7	ГХ 78746						Form filed by I Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	Acquired, Disposed o	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transaction Code (Instr. 8) Code V	nAcquired Disposed (Instr. 3, 4	(A) or of (D)	Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
Reminder: Re	port on a separate lin	e for each cl	ass of sec				or indirectly			
					Perso inform	ns who rest nation cont	spond to the collect tained in this form ond unless the for	are not	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

displays a currently valid OMB control

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 E S (1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	,
Director Stock Option (right to buy)	\$ 7.28	05/17/2016		А	24,000	<u>(1)</u>	05/16/2026	Common Stock	24,000	

Edgar Filing: Aeglea BioTherapeutics, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
GEORGIOU GEORGE C/O AEGLEA BIOTHERAPEUTICS, INC. 901 S. MOPAC EXPRESSWAY, SUITE 250 AUSTIN, TX 78746	Х					
Signatures						
/s/ Charles N. York II, by power of attorney	05/19/	2016				
**Signature of Reporting Person	Date	e				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option vests and becomes exercisable in 36 equal monthly installments beginning on June 17, 2016, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.